Perifosine and Docetaxel in Patients With Relapsed Epithelial Ovarian Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
Ovarian Cancer
Interventions
DRUG

Perifosine

Loading Dose = 100 mg by mouth (PO) every 6 hours, followed by 50 mg by mouth (PO) daily

DRUG

Docetaxel

75 mg/m\^2 by vein over 1 hour every 4 weeks

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Keryx Biopharmaceuticals

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00431054 - Perifosine and Docetaxel in Patients With Relapsed Epithelial Ovarian Cancer | Biotech Hunter | Biotech Hunter